Kappa Opioid Receptors Act as a Brake on Excitatory Brain Signaling in the Hippocampus

Kappa opioid agonists selectively blocked glutamate and dynorphin release from hippocampal nerve terminals, while mu and delta agonists had no effect.

Gannon, R L et al.·Neurochemical research·1992·Preliminary Evidencein-vitro
RPEP-00231In VitroPreliminary Evidence1992RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Kappa agonists U-62,066E and ethylketocyclazocine inhibited potassium-evoked glutamate and dynorphin B release from mossy fiber synaptosomes. Mu (DAGO) and delta (DPDPE) agonists were inactive.

Key Numbers

How They Did This

Guinea pig hippocampal mossy fiber synaptosomes were isolated. Potassium-evoked release of L-glutamate and dynorphin B was measured in the presence of opioid receptor subtype-selective agonists.

Why This Research Matters

Kappa receptors on hippocampal mossy fibers can dial down excitatory signaling. This natural brake system could protect the brain from seizures and excitotoxic damage.

The Bigger Picture

The hippocampus is central to memory and is vulnerable to seizures and excitotoxic damage. Having kappa opioid receptors that specifically reduce glutamate release provides a built-in protective mechanism that could be therapeutically relevant for epilepsy and brain injury.

What This Study Doesn't Tell Us

In vitro study using isolated nerve terminals. May not reflect the complex regulation in intact hippocampal circuits. Guinea pig results may differ from humans.

Questions This Raises

  • ?Could kappa agonists be developed as anti-seizure medications targeting the hippocampus?
  • ?Does chronic kappa receptor activation in the hippocampus affect memory formation?

Trust & Context

Key Stat:
Kappa-selective effect Only kappa agonists inhibited neurotransmitter release — mu and delta agonists were completely inactive at these synapses
Evidence Grade:
Preliminary — in vitro study using isolated nerve terminals (synaptosomes) from guinea pig hippocampus. Clean pharmacology but removed from intact brain circuit dynamics.
Study Age:
Published in 1992 (34 years ago). The role of kappa receptors in hippocampal regulation is now well-established.
Original Title:
Kappa opioid agonists inhibit transmitter release from guinea pig hippocampal mossy fiber synaptosomes.
Published In:
Neurochemical research, 17(8), 741-7 (1992)
Database ID:
RPEP-00231

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What are mossy fiber synaptosomes?

Mossy fibers are major excitatory pathways in the hippocampus. Synaptosomes are isolated nerve terminals used to study neurotransmitter release in a controlled setting without the complexity of intact brain circuits.

Why is reducing glutamate release important?

Glutamate is the brain's main excitatory neurotransmitter. Too much of it causes excitotoxicity — cell damage from overstimulation — which contributes to seizures, stroke damage, and neurodegenerative diseases. Kappa receptors provide a natural mechanism to prevent this.

Read More on RethinkPeptides

Cite This Study

RPEP-00231·https://rethinkpeptides.com/research/RPEP-00231

APA

Gannon, R L; Terrian, D M. (1992). Kappa opioid agonists inhibit transmitter release from guinea pig hippocampal mossy fiber synaptosomes.. Neurochemical research, 17(8), 741-7.

MLA

Gannon, R L, et al. "Kappa opioid agonists inhibit transmitter release from guinea pig hippocampal mossy fiber synaptosomes.." Neurochemical research, 1992.

RethinkPeptides

RethinkPeptides Research Database. "Kappa opioid agonists inhibit transmitter release from guine..." RPEP-00231. Retrieved from https://rethinkpeptides.com/research/gannon-1992-kappa-opioid-agonists-inhibit

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.